Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy

• Main Authors: Sony Tuteja (Author), Ramzi G. Salloum (Author), Amanda L. Elchynski (Author), D. Max Smith (Author), Elizabeth Rowe (Author), Kathryn V. Blake (Author), Nita A. Limdi (Author), Christina L. Aquilante (Author), Jill Bates (Author), Amber L. Beitelshees (Author), Amber Cipriani (Author), Benjamin Q. Duong (Author), Philip E. Empey (Author), Christine M. Formea (Author), J. Kevin Hicks (Author), Pawel Mroz (Author), David Oslin (Author), Amy L. Pasternak (Author), Natasha Petry (Author), Laura B. Ramsey (Author), Allyson Schlichte (Author), Sandra M. Swain (Author), Kristen M. Ward (Author), Kristin Wiisanen (Author), Todd C. Skaar (Author), Sara L. Van Driest (Author), Larisa H. Cavallari (Author), Jeffrey R. Bishop (Author), for the IGNITE Pharmacogenetics Working Group (Author)
• Format: Book
• Published: Wiley, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract There is growing interest in utilizing pharmacogenetic (PGx) testing to guide antidepressant use, but there is lack of clarity on how to implement testing into clinical practice. We administered two surveys at 17 sites that had implemented or were in the process of implementing PGx testing...